Autolus Therapeutics plc Asset Resilience Ratio

Latest as of June 2026: 6.13%

Autolus Therapeutics plc asset resilience ratio. Autolus Therapeutics plc (6A3A) has an Asset Resilience Ratio of 6.13% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 6A3A defensive asset coverage days to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€30.22 Million

≈ $35.33 Million USD Cash + Short-term Investments

Total Assets

€493.23 Million

≈ $576.63 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Autolus Therapeutics plc (2023–2025)

Asset resilience ratio of Autolus Therapeutics plc from 2023 to 2025. This chart shows how Autolus Therapeutics plc's Asset Resilience Ratio has changed over time. Read Autolus Therapeutics plc (6A3A) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Autolus Therapeutics plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Autolus Therapeutics plc.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€30.22 Million	6.13%
Total Liquid Assets	€30.22 Million	6.13%

Asset Resilience Insights

Limited Liquidity: Autolus Therapeutics plc maintains only 6.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Autolus Therapeutics plc Industry Peers by Asset Resilience Ratio

Compare Autolus Therapeutics plc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Chengdu Easton Biopharmaceuticals Co Ltd SHG:688513	Biotechnology	35.16%
China Resources Boya Bio pharmaceutical Group Co Ltd SHE:300294	Biotechnology	23.15%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Achieve Life Sciences Inc F:SP4P	Biotechnology	3.60%

Autolus Therapeutics plc Asset Resilience Ratio by Year (2023–2025)

Autolus Therapeutics plc asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Autolus Therapeutics plc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	33.37%	€196.58 Million ≈ $229.82 Million	€589.07 Million ≈ $688.68 Million	-12.70pp
2024-12-31	46.08%	€360.64 Million ≈ $421.63 Million	€782.73 Million ≈ $915.09 Million	--
2023-12-31	0.00%	€0.00 ≈ $0.00	€375.38 Million ≈ $438.86 Million	--

pp = percentage points

About Autolus Therapeutics plc

F:6A3A Germany Biotechnology

Market Cap

$407.64 Million

€348.67 Million EUR

Market Cap Rank

#12983 Global

#1380 in Germany

Share Price

€1.31

Change (1 day)

-4.38%

52-Week Range

€1.06 - €2.16

All Time High

€40.10